Elaine T. Lam

Elaine T. Lam

Oncology
1665 Aurora Ct
1st Floor
Aurora, CO 80045

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 85 publications

Inter-Reader Agreement for CT and MRI LI-RADS Version 2018: An Individual Participant Data Meta-Analysis.

Inter-Reader Agreement for CT and MRI LI-RADS Version 2018: An Individual Participant Data Meta-Analysis.

Journal: Journal of magnetic resonance imaging : JMRI
Published: April 22, 2026

Tyrosine kinase inhibitors affect sweet taste and dysregulate fate selection of specific taste bud cell subtypes via KIT inhibition.

Tyrosine kinase inhibitors affect sweet taste and dysregulate fate selection of specific taste bud cell subtypes via KIT inhibition.

Journal: Development (Cambridge, England)
Published: September 19, 2025

Tyrosine kinase inhibitors affect sweet taste and dysregulate fate selection of specific taste cell subtypes via KIT inhibition.

Tyrosine kinase inhibitors affect sweet taste and dysregulate fate selection of specific taste cell subtypes via KIT inhibition.

Journal: bioRxiv : the preprint server for biology
Published: September 02, 2025

Determinants of pancreatic tropism in metastatic renal cell carcinoma.

Determinants of pancreatic tropism in metastatic renal cell carcinoma.

Journal: JCI insight
Published: May 22, 2025

Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study.

Squamous cell carcinoma of unknown primary (SCCUP): a genomic landscape study.

Journal: ESMO open
Published: April 21, 2025

A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer.

A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer.

Journal: ESMO open
Published: February 06, 2025

Clinical features and mutational frequency of renal cell carcinoma from patients undergoing kidney transplant evaluation.

Clinical features and mutational frequency of renal cell carcinoma from patients undergoing kidney transplant evaluation.

Journal: Frontiers in oncology
Published: November 11, 2024

Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial.

Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial.

Journal: The Lancet. Oncology
Published: October 09, 2024

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.

Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma.

Journal: The New England journal of medicine
Published: August 21, 2024

Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab.

Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab.

Journal: Scientific reports
Published: July 22, 2024

Clinical and Genomic Features of Patients with Renal Cell Carcinoma and Advanced Chronic Kidney Disease: Analysis of a Multi-Institutional Database.

Clinical and Genomic Features of Patients with Renal Cell Carcinoma and Advanced Chronic Kidney Disease: Analysis of a Multi-Institutional Database.

Journal: Cancers
Published: April 22, 2024

NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.

NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024.

Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: February 23, 2024
Showing 1-12 of 85

Last Updated: 09/26/2026